|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Meta-analysis on integrative medicine for the treatment of malignant ascites: a comparative study显示文摘OBJECTIVE: To compare the efficacy of integrated Chinese and Western Medicine with that of only Western Medicine for the treatment of malignant ascites.METHODS: All randomized controlled trials(January 2004 to March 2013) from the China National Knowledge Infrastructure Database, Chinese Biomedical Literature Database, and Wanfang Database were searched with keywords. Meta-analysis was conducted by combining the odds ratios of the individual studies. Review Manager 5.0 was used for the analysis.RESULTS: One thousand one hundred and fifty-six patients from 19 randomized controlled trails were included. Of them, 630 patients were treated with integrated Chinese and Western Medicine(the integrative group), and 526 patients were treated with Western Medicine alone(the control group). The Meta-analysis showed that the total effective rate was 78.73% in the integrated group, and 59.13% in the control group. The effective percentage was sig-nificantly higher in the integrative group than that of the control group [OR = 2.85, 95% CI(2.16,3.74),P < 0.01].CONCLUSION: The short-term curative effect in the integrative group was better than that in the control group. Integrative medicine may be beneficial for malignant ascites. | Li Yuan Lou Yanni Deng Bo Jia Liqun | 2015 | Journal of Traditional Chinese Medicine2015，35，1： | 5 |
| 2 | Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms显示文摘OBJECTIVE: To evaluate the efficacy of Shengjiangxiexin decoction(SXD), prepared with a formula from Traditional Chinese Medicine(TCM), in reducing irinotecan-induced hematological and gastrointestinal toxicities in patients with UDP-glucuronosyltransferase(UGT)1A1*28 and UGT1A1*6 polymorphisms.METHODS: This clinical trial included 115 patients receiving irinotecan combined with 5-fluorouracil plus l-leucovorin(FOLFIRI) treatment. All patients consented to UGT1A1*28 and *6 gene polymorphism detection prior to chemotherapy. SXD were administered from 1 day prior to chemotherapy to6 day post chemotherapy. Chemotherapy induced adverse reactions(neutropenia, diarrhea, nausea,vomiting, anorexia and infection) were recorded,and short-term effect of chemotherapy was evaluated regularly.RESULTS: A total of 50 patients had *1/*1 wild genotype, 58 patients had single allele variants with genotype *1/*6 or *1/*28, and 7 patients had twoalleles variants with genotype *6/*6, *28/*28 or *6/*28. In *1/*6 or *1/*28 patients(high risk group), 9patients(15.5%) developed Ⅰ-Ⅱ grade diarrhea and no patient developed severe diarrhea; neutropenia occurred in 19 patients(32.8%) and only 3 patients(8.6%) developed sever neutropenia. There were no significant differences in any toxic effects(neutropenia, diarrhea, nausea, vomiting, anorexia or infection) between *6 or *28 variant patients(high risk group) and wild type patients. No sever toxicity was found in high risk two alleles variants patients(*6/*6, *6/*28 or *28/*28). No significant differences were observed between UGT1A1*6/*28polymorphisms and clinical response of chemotherapy.CONCLUSION: SXD could significantly reduce irinotecan-induced hematological and gastrointestinal toxicities in UGT1A1*28 or *6 variant patients(high risk group), while this treatment didn't affect clinical response of chemotherapy. | Deng Bo Jia Liqun Tan Huangying Lou Yanni Li Xue Li Yuan Yu Lili | 2017 | Journal of Traditional Chinese Medicine2017，37，1： | 5 |
| 3 | Safety and efficacy of Tongkuaixiao ointment in reliving cancer-induced pain: a multicenter double-blind placebo-controlled randomized trial显示文摘OBJECTIVE: To evaluate the safety and efficacy of Tongkuaixiao ointment(TKXO) in treating moderate-to-severe cancer induced somatalgia.METHODS: Totally 130 patients with moderateto-severe cancer induced somatalgia were randomly divided into a TKXO group and a control group.The patients were treated with either TKXO applied externally or placebo, with opioid analgesics orally at the same time. Observation parameters were included numerical rating scale(NRS) scores,analgesic efficacy, initiation effective time, persistent analgesic time, equivalent morphine dose,National Comprehensive Cancer Network(NCCN)grade in Impact of Pain Measurement Scores, and safety and satisfaction extent investigation.RESULTS: NRS scores and NCCN grade in Impact of Pain Measurement Scores decreased significantly after 5-days' treatment in the two groups(P <0.0001). Compared to the control group, initiation effective time was significantly shorter(P < 0.05)and persistent analgesic time was significantly longer(P < 0.01), equivalent oral morphine doses of the first day and the whole treatment course were significantly decreased in the TKXO treatment group(P < 0.01 or P < 0.05). No obvious adverse effects were found in the TKXO group.CONCLUSION: TKXO combined with opioid analgesics possesses the advantages of high efficacy,fast action, long persistent action, safety and convenience in use, and it can reduce the dose of opioid. | Tan Huangying Zhu Shijie Li Tong Feng Li Zhang Xia Li Yuan Lou Yanni Liu Meng Wan Donggui Li Peiwen Jia Liqun Deng Bo | 2016 | Journal of Traditional Chinese Medicine2016，36，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员